Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - sodium amidotrizoate, quantity: 40 mg/ml; amidotrizoate meglumine, quantity: 260 mg/ml - injection, solution - excipient ingredients: water for injections; sodium calcium edetate - intravenous and retrograde urography. computerized tomography. also for all angiographic examinations as well as for aminography, arthrography, intraoperative cholangiography, fistulography, hysterosalpingography, splenoportography, vesiculography and others. urografin is not to be used for myelography, ventriculography of cisternography, since it is likely to provoke neurotoxic symptoms in these examinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - amidotrizoate meglumine, quantity: 260 mg/ml; sodium amidotrizoate, quantity: 40 mg/ml - injection, intravenous infusion - excipient ingredients: sodium calcium edetate; water for injections - intravenous and retrograde urography. computerized tomography. also for all angiographic examinations as well as for aminography, arthrography, intraoperative cholangiography, fistulography, hysterosalpingography, splenoportography, vesiculography and others. urografin is not to be used for myelography, ventriculography of cisternography, since it is likely to provoke neurotoxic symptoms in these examinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - sodium amidotrizoate, quantity: 100 mg/ml; amidotrizoate meglumine, quantity: 660 mg/ml - injection, solution - excipient ingredients: water for injections; disodium edetate - intravenous and retrograde urography. computerised tomography. also for all angiographic examinations as well as for amniography, arthrography, intraoperative cholangiography, fistulography, hysterosalpingography, splenoportography, vesiculography and others. urografin is not to be used for myelography, ventriculography or cisternography since it is likely to provoke neurotoxic symptoms in the examinations.

Israel - English - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Israel - English - Ministry of Health

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 0.9 %w/v - sodium chloride - sodium chloride - treatment of isotonic extracellular dehydration. treatment of sodium depletion. vehicle or diluent of compatible drugs for parenteral administration.

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - amidotrizoate meglumine, quantity: 660 mg/ml; sodium amidotrizoate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium calcium edetate; water for injections - intravenous and retrograde urography. computerized tomography. also for all angiographic examinations as well as for aminography, arthrography, intraoperative cholangiography, fistulography, hysterosalpingography, splenoportography, vesiculography and others. urografin is not to be used for myelography, ventriculography of cisternography, since it is likely to provoke neurotoxic symptoms in these examinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Australia - English - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

United States - English - NLM (National Library of Medicine)

onpharma, inc. - sodium bicarbonate (unii: 8mdf5v39qo) (bicarbonate ion - unii:hn1zra3q20) - sodium bicarbonate 84 mg in 1 ml - sodium bicarbonate inj., 8.4% usp neutralizing additive solution is indicated to hasten onset of analgesia and reduce injection pain, by adjusting commercial preparations of lidocaine w/ epinephrine anesthetic solution to a more physiologic ph. not for use as a systemic alkalizer. barash pg, cullen bf, stoelting rk, clinical anesthesia (4th ed. 2001 lippincott williams and wilken). bhatt h, powell kj, jean da, first aid for the anesthesiology boards, an insider's guide (2011, mcgraw-hill medical). cepeda ms, tzortzopoulou a, thackrey m, hudcova j, arora gandhi p, schumann r., adjusting the ph of lidocaine for reducing pain on injection. cochrane database of systematic reviews 2010, issue 12. art. no.: cd006581. chu lf, clinical anesthesiology board review(2005, mcgraw-hill medical). malamed sf,handbook of local anesthesiology(5th ed. 2004, elsevier mosby). miller rd, miller's anesthesia (6th ed. 2004). stoelting rk, miller rd,basics of anesthesia(5th ed. 2007, churchill livingstone el

United States - English - NLM (National Library of Medicine)

mylan institutional llc - sodium phenylacetate (unii: 48n6u1781g) (phenylacetic acid - unii:er5i1w795a), sodium benzoate (unii: oj245fe5eu) (benzoic acid - unii:8skn0b0mim) - sodium phenylacetate 100 mg in 1 ml - sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. during acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [see warnings and precautions (5) ]. none. available data with sodium phenylacetate and sodium benzoate injection use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with sodium phenylacetate and sodium benzoate injection. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. g